PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance

Xiaoming Jia; Mahmoud Al Rifai; Anum Saeed; Christie M. Ballantyne; Salim S. Virani

doi:10.2147/VHRM.S275739

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance

Xiaoming Jia, Mahmoud Al Rifai, Anum Saeed, Christie M. Ballantyne, Salim S. Virani

Research output: Contribution to journal › Review article › peer-review

10 Citations (Scopus)

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholesterol (LDL-C) and impact on cardiovascular outcomes. Since the approval of commercial use for PCSK9 inhibitors in 2015, we have also gained significant experience in the use of these therapeutics in the real-world setting. In this article, we review current guideline recommendations, clinical trial evidence on efficacy and safety as well as data on cost-effectiveness, prescription and adherence. We focus primarily on the monoclonal antibody class of PCSK9 inhibitors in this review while also touching on other types of therapeutics that are under development.

Original language	English
Pages (from-to)	555-566
Number of pages	12
Journal	Vascular Health and Risk Management
Volume	18
DOIs	https://doi.org/10.2147/VHRM.S275739
Publication status	Published - 2022
Externally published	Yes

Keywords

CVD prevention
PCSK9 inhibitor
lipids

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2147/VHRM.S275739

Cite this

@article{9524ea1af70a43c0b45e38094a21ee96,

title = "PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance",

abstract = "Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholesterol (LDL-C) and impact on cardiovascular outcomes. Since the approval of commercial use for PCSK9 inhibitors in 2015, we have also gained significant experience in the use of these therapeutics in the real-world setting. In this article, we review current guideline recommendations, clinical trial evidence on efficacy and safety as well as data on cost-effectiveness, prescription and adherence. We focus primarily on the monoclonal antibody class of PCSK9 inhibitors in this review while also touching on other types of therapeutics that are under development.",

keywords = "CVD prevention, PCSK9 inhibitor, lipids",

author = "Xiaoming Jia and {Al Rifai}, Mahmoud and Anum Saeed and Ballantyne, {Christie M.} and Virani, {Salim S.}",

note = "Publisher Copyright: {\textcopyright} 2022 Jia et al.",

year = "2022",

doi = "10.2147/VHRM.S275739",

language = "English",

volume = "18",

pages = "555--566",

journal = "Vascular Health and Risk Management",

issn = "1176-6344",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - PCSK9 Inhibitors in the Management of Cardiovascular Risk

T2 - A Practical Guidance

AU - Jia, Xiaoming

AU - Al Rifai, Mahmoud

AU - Saeed, Anum

AU - Ballantyne, Christie M.

AU - Virani, Salim S.

PY - 2022

Y1 - 2022

N2 - Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholesterol (LDL-C) and impact on cardiovascular outcomes. Since the approval of commercial use for PCSK9 inhibitors in 2015, we have also gained significant experience in the use of these therapeutics in the real-world setting. In this article, we review current guideline recommendations, clinical trial evidence on efficacy and safety as well as data on cost-effectiveness, prescription and adherence. We focus primarily on the monoclonal antibody class of PCSK9 inhibitors in this review while also touching on other types of therapeutics that are under development.

AB - Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholesterol (LDL-C) and impact on cardiovascular outcomes. Since the approval of commercial use for PCSK9 inhibitors in 2015, we have also gained significant experience in the use of these therapeutics in the real-world setting. In this article, we review current guideline recommendations, clinical trial evidence on efficacy and safety as well as data on cost-effectiveness, prescription and adherence. We focus primarily on the monoclonal antibody class of PCSK9 inhibitors in this review while also touching on other types of therapeutics that are under development.

KW - CVD prevention

KW - PCSK9 inhibitor

KW - lipids

UR - http://www.scopus.com/inward/record.url?scp=85134466486&partnerID=8YFLogxK

U2 - 10.2147/VHRM.S275739

DO - 10.2147/VHRM.S275739

M3 - Review article

C2 - 35898405

AN - SCOPUS:85134466486

SN - 1176-6344

VL - 18

SP - 555

EP - 566

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

ER -

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this